ANGIOFLUX Sulodexide 250LSU Soft Gel Capsule 50's

Sulodexide (Angioflux) is used in the treatment of various vascular disorders with increased risk of thrombosis, including chronic venous ulcers, intermittent claudication, peripheral arterial occlusive disease, post myocardial infarction and diabetic nephropathy.

 

1-2 softgel capsules twice daily before meals.

 

Hypersensitivity to the active substance or to one of the excipients.
As the molecular structure is similar to heparin, do not administer sulodexide (Angioflux) to patients hypersensitive to heparin and heparinoids.

 

Patients should consult their doctors for instructions as to the correct way of administering the drug.

 

In all cases, where treatment is in progress with anticoagulants, we recommend periodically controlling the hemocoagulation parameters.

 

In pregnant women and very early infancy, the product should be administered in case of effective need, under the direct control of a doctor.
For cautionary reasons, we advise against use during pregnancy, even if the fetal toxicity studies have not demonstrated any embryo-fetus toxicity.

 

Store at temperatures not exceeding 30°C.

 

Pharmacology: Sulodexide (Angioflux) is a highly purified mixture of glycosaminoglycans consisting of 80% low molecular weight heparin and 20% dermatan sulfate, total components being from porcine origin. Because of the low molecular weights of both fractions, sulodexide (Angioflux) has a more extensive oral absorption compared to unfractionated heparin. Compared to other glycosaminoglycans, sulodexide (Angioflux) has a prolonged half-life and reduced effect on systemic clotting and bleeding. Given orally, subcutaneously, or by intravenous injection, sulodexide (Angioflux) exhibits thrombolytic and fibrinolytic activity thereby demonstrating efficacy in the treatment of thromboembolic disease. These antithrombotic and antithrombin properties are of great pharmacological value and makes sulodexide (Angioflux) a suitable drug for the prophylaxis and treatment of arterial and venous peripheral diseases.
The main mechanism can be identified in a dose-dependent inhibition of the activated coagulation factor X, while the limited interference effect with thrombin avoid the consequences of an anticoagulant action. Sulodexide (Angioflux) exerts potent lipolytic activity, as well as activity related to proteoglycan synthesis by smooth muscle cells, associated with suppression of cell proliferation and inhibition of a significant part of atheromatous plaque development. At the same time, sulodexide (Angioflux) inhibits migration of smooth muscle cells towards the innermost layer, as a result of the drug's antithrombin and anti-platelet aggregation effect. The marked efficacy of sulodexide (Angioflux) derives from its dual action of catalyzing the inhibition of thrombin by antithrombin III (ATIII) and by heparin cofactor II (HCII), with the added advantage of not increasing bleeding. Sulodexide (Angioflux) possesses marked systemic fibrinolytic activity due to the liberation of tissue plasminogen activator (tPA), with marked functional and antigenic reduction of plasminogen activator inhibitor-1 (PAI-1), and a reduction in plasma fibrinogen concentration, favoring the reduction of blood viscosity.
In summary, sulodexide (Angioflux) has very effective antithrombotic and antithrombin activity, with efficacy and safety demonstrated in a wide range of vascular pathologies.